Drug intelligence / Profile preview

MTP55

Development stage: Preclinical
Lead developer: Medytox
Administration: Injection

Overview

MTP55 is a medical device filler currently in the discovery phase of development by Medytox, specifically targeted for lip augmentation. As a dermal filler, it is designed to be injected into the lip tissue to provide physical volume, structural support, and aesthetic contouring. While specific chemical composition details are not publicly disclosed in early discovery, Medytox typically utilizes hyaluronic acid-based technologies in its aesthetic portfolio. The product is part of Medytox's expanding pipeline of medical devices aimed at the global medical aesthetics market.

Beyond the preview

Go deeper on MTP55.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTP55.

Explore the full profile